Antibiotic activities against S. aureus during P. aeruginosa co-infection
Antibiotic activities against S. aureus during P. aeruginosa co-infection
批准号:
10318912
负责人:
Brian Patrick Conlon
金额:
$38.47万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-01-01 至 2022-12-31
关键词:
AdjuvantAlginatesAminoglycoside resistanceAminoglycosidesAnaerobic BacteriaAntibiotic ResistanceAntibiotic TherapyAntibiotic susceptibilityAntibioticsBacteriaBacterial InfectionsBiological AssayCathetersCell Membrane PermeabilityCell WallChemosensitizationCiprofloxacinClinicClinicalComplexDataDevelopmentDropsEnvironmentEnzymesExhibitsFailureFluoroquinolonesFutureGenotypeGlycopeptidesGrowthImmunologic FactorsImplantInfectionLeadLength of StayMeasurementMeasuresMediatingMicrobial BiofilmsModelingMolecularMusNutrientOutcomeOxacillinOxidesOxygenPatientsPenetrationPeptidoglycanPhysiologicalPlayPopulationPredispositionProductionProton-Motive ForcePseudomonas aeruginosaPulmonary Cystic FibrosisQuantitative Reverse Transcriptase PCRRegulationReporterRespirationRoleStaphylococcus aureusTestingTobramycinTreatment FailureTreatment outcomeVancomycinWestern BlottingWorkantibiotic tolerancebactericidebeta-Lactamsburn modelburn woundclinically relevantclinically significantco-infectioncystic fibrosis patientsexperienceexperimental studyimprovedin vivomicroorganismmortalitymouse modelmutantnovelquorum sensingrhamnolipidsuccesssurfactantuptake
中文摘要
总结抽象
英文摘要
Summary Abstract
Predicting the efficacy of an antibiotic in a patient is a critical component of successfully treating infection.
Currently, there is an over-reliance on susceptibility assays involving pure bacterial cultures and controlled
growth conditions. These conditions are drastically different to those experienced by the bacteria during
infection. Hence, these assays fail to account for extrinsic factors that influence antibiotic susceptibility in the
infection environment. This contributes to unacceptable rates of treatment failure. Staphylococcus aureus is
responsible for numerous difficult-to-treat infections and antibiotic treatment failure is common. The
identification of novel extrinsic factors that significantly influence S. aureus antibiotic susceptibility in vivo will
greatly improve our ability to predict antibiotic efficacy in patients, leading to improved treatment outcomes.
These factors may include host interactions, nutrient and oxygen availability and interactions with other
microorganisms during polymicrobial infection.
Our preliminary studies demonstrate that P. aeruginosa produced molecules dramatically alter S.
aureus antibiotic susceptibility. We find the production of these molecules is highly variable among P.
aeruginosa clinical isolates. Preliminary experiments in mice suggest these interactions play an important role
in determining antibiotic efficacy in vivo.
We hypothesize that P. aeruginosa strongly influences S. aureus antibiotic susceptibility in patients
during polymicrobial infection.
In Aim 1, we propose to elucidate the molecular mechanisms responsible for this altered antibiotic efficacy.
Elucidation of these mechanisms will improve our understanding of S. aureus antibiotic tolerance and may also
lead to the development of novel adjuvants for the eradication of S. aureus populations.
In Aim 2, to determine the importance of P. aeruginosa/S. aureus interactions in patients, we will
examine clinical isolate pairs from burn and cystic fibrosis patients.
In Aim 3, to determine the relevance of these interactions during infection, we will examine antibiotic
efficacy against S. aureus mono-infection and during co-infection with P. aeruginosa using two complimentary
mouse models of infection.
Together, these experiments promise to reveal the role of bacterial interaction in determining the
outcome of antibiotic treatment of S. aureus. This will facilitate the future development of more sophisticated,
more accurate susceptibility determination and improved treatment outcomes in patients.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.7554/elife.80246
发表时间:
2023-03-06
期刊:
eLife
影响因子:
7.7
作者:
[Sidders AE, Kedziora KM, Arts M, Daniel JM, de Benedetti S, Beam JE, Bui DT, Parsons JB, Schneider T, Rowe SE, Conlon BP]
通讯作者:
Conlon BP
Harnessing ultrasound-stimulated phase change contrast agents to improve antibiotic efficacy against methicillin-resistant Staphylococcus aureus biofilms.
利用超声刺激的相位变化对比剂,以提高针对耐甲氧西林的金黄色葡萄球菌生物膜的抗生素疗效。
DOI:
10.1016/j.bioflm.2021.100049
发表时间:
2021-12
期刊:
Biofilm
影响因子:
6.8
作者:
[Durham PG, Sidders AE, Beam JE, Kedziora KM, Dayton PA, Conlon BP, Papadopoulou V, Rowe SE]
通讯作者:
Rowe SE
DOI:
10.1128/spectrum.04061-22
发表时间:
2023-02-14
期刊:
Microbiology spectrum
影响因子:
3.7
作者:
[]
通讯作者:
DOI:
10.3390/antibiotics12030455
发表时间:
2023-02-24
期刊:
ANTIBIOTICS-BASEL
影响因子:
4.8
作者:
[Parsons, Joshua. B., Westgeest, Annette. C., Conlon, Brian. P. B., Fowler, Vance. G., Jr.]
通讯作者:
Fowler, Vance. G., Jr.
The contribution of respiratory burst to antibiotic failure in Staphylococcus aureus bacteremia
-
批准号:10666777
-
项目类别:
-
资助金额:$67.46万
-
财政年份:2022
-
负责人:Brian Patrick Conlon
-
依托单位:
Diabetes and Antibiotic Treatment Failure
-
批准号:10564510
-
项目类别:
-
资助金额:$71.21万
-
财政年份:2022
-
负责人:Brian Patrick Conlon
-
依托单位:
Identifying the contribution of zinc limitation to antibiotic tolerance during S. aureus infection
-
批准号:10192892
-
项目类别:
-
资助金额:$24.09万
-
财政年份:2021
-
负责人:Brian Patrick Conlon
-
依托单位:
Antibiotic activities against S. aureus during P. aeruginosa co-infection
-
批准号:9917929
-
项目类别:
-
资助金额:$4.64万
-
财政年份:2018
-
负责人:Brian Patrick Conlon
-
依托单位:
海外基金